Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.41 |
| ▸ | ATM | Q13315 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.41 |
| ▸ | PTGER4 | P35408 | 3/20 | 0.41 |
| ▸ | PTGER3 | P43115 | 3/20 | 0.41 |
| ▸ | PTGER2 | P43116 | 3/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | PTGER1 | P34995 | 2/20 | 0.40 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Benzene SCHEMBL2292646 | 0.86 | KDM4E (0.43) | SMN1; SMN2L3MBTL1ATMKMT2APTGER4 | |
| SCHEMBL2293253 | 0.86 | SMN1; SMN2 (0.55) | SMN1; SMN2L3MBTL1ATMTDP1KMT2A | |
| SCHEMBL1200926 | 0.85 | LMNA (0.43) | SMN1; SMN2L3MBTL1ATMKMT2AHPGD | |
| SCHEMBL1201013 | 0.84 | KMT2A (0.47) | SMN1; SMN2L3MBTL1ATMTDP1KMT2A | |
| SCHEMBL2294671 | 0.84 | SMN1; SMN2 (0.56) | SMN1; SMN2L3MBTL1ATMTDP1KMT2A | |
| SCHEMBL1201118 | 0.80 | CDK4 (0.41) | SMN1; SMN2L3MBTL1TDP1KMT2APTGER4 | |
| SCHEMBL2293617 | 0.79 | TRIM24 (0.49) | SMN1; SMN2TDP1KMT2A | |
| SCHEMBL2289750 | 0.78 | CCNB2 (0.40) | SMN1; SMN2L3MBTL1ATMKMT2AHPGD | |
| SCHEMBL2288078 | 0.77 | FFAR1 (0.42) | SMN1; SMN2KMT2AHPGDFFAR1 | |
| SCHEMBL1200524 | 0.76 | CDK4 (0.38) | SMN1; SMN2ATMKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2149545-B1 | METHOD FOR PRODUCING BENZALDEHYDE COMPOUND | SUMITOMO CHEMICAL CO (JP) | 2016-10-05 | — | — | EP | disclosed |
| US-7994367-B2 | Method for producing benzaldehyde compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2011-08-09 | — | — | US | disclosed |
| US-20100210879-A1 | METHOD FOR PRODUCING BENZALDEHYDE COMPOUND | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-08-19 | — | — | US | disclosed |
| EP-2149545-A1 | METHOD FOR PRODUCING BENZALDEHYDE COMPOUND | Sumitomo Chemical Company, Limited (JP) | 2010-02-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100210879-A1 | METHOD FOR PRODUCING BENZALDEHYDE COMPOUND | NQO1, C9, TRPA1 | SMN1; SMN2 3093/4885L3MBTL1 2751/4885ATM 2333/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.